TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients underwent ESD for gastric adenoma or cancer~Exclusion Criteria:~* subjects with previous gastric surgery~* subjects taking aspirin, anticoagulant, or antiplatelet agent~* subjects having malignancy except gastric cancer~* pregnant or breast-feeding women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pantoprazole (Type: OTHER): controls Pantoprazole 40mg qd for 28days
- Pantoprazole + Rebamipde (Type: ACTIVE_COMPARATOR): Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>/= 18 years of age~* chronic hepatitis C~* informed consent to data collection~Exclusion Criteria:~* co-infection with HIV or Hepatitis B Virus (HBV)~* previous treatment with peginterferon and/or ribavirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ibuprofen Use on Post-operative Pain Following Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA grade I-II patients~* Aged 18-65 years~Exclusion Criteria:~* History of allergies or hypersensitivity to the aforementioned agents~* Renal, hepatic or gastrointestinal disease~* Significant cognitive impairment~* Recent use of long-term nonsteroid anti-inflammatory and opioids~* Oral anticoagulant use or known bleeding disorders~* Diabetes or any other neuropathic diseases~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Acetaminophen group (Type: ACTIVE_COMPARATOR): The acetaminophen group (n=35) received 1000 of mg acetaminophen intravenously in 100 mL saline at the end of the cholecystectomy.
- Ibuprofen group (Type: EXPERIMENTAL): The ibuprofen group (n=36) was administered 800 mg of ibuprofen at the end of the cholecystectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>=5kg~* Plasmodium falciparum infection with parasite density \> 2000/µL~* Fever or history of fever~* Able to be treated by oral route~* No signs of severe malaria~* No known allergy to study drugs~* No other severe illnesses or underlying diseases~* No known pregnancy or negative urinary pregnancy test for women of child bearing age~* No participation in another ongoing clinical study~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Artesunate + Amodiaquine (Type: EXPERIMENTAL): Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: \>= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy~Exclusion Criteria:~* Participants have a history of Type 1 Diabetes Mellitus~* Participants taking insulin or thiazolidinediones (TZDs: peroxisome proliferator-activated receptor \[PPAR\]-gamma agonists)~* Participants who have a contraindication to metformin or sitagliptin

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-0893 + Sitagliptin (Type: EXPERIMENTAL): None
- MK-0893 + Metformin (Type: EXPERIMENTAL): None
- Sitagliptin + Metformin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Epinephrine and Clonidine as Adjuvants to Lidocaine in Axillary Brachial Plexus Block.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1-2~* Patients age \>18 years~* Undergoing elective upper limb (forearm, wrist or hand) surgery.~Exclusion Criteria:~* Contraindications to regional anaesthesia~* Hypersensitivity to amide local anaesthetics.~* Chronic pain~* Language barrier~* Neuromuscular disorders or peripheral neuropathy~* H/o postural hypotension or autonomic dysfunction.~* Patients with a known sensitivity for local anaesthetics~* Body mass index \> 35~* History of hepatic and renal insufficiency~* Pregnancy~* Cognitive or psychiatric disorder~* Cardiac conduction abnormality.~* Anti arrythmic or adrenergic medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lidocaine 2% with normal saline (Type: ACTIVE_COMPARATOR): Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
- lidocaine 2% with clonidine (Type: EXPERIMENTAL): Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Real-World Evidence Study to Evaluate Oral Health Related Quality of Life Using an Anti-Sensitivity Toothpaste

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of consent indicating that the participant has been informed of all pertinent aspects of the study.~* The participant must be able to complete all activities as shown in the Schedule of Activities independently on their smart devices.~* Participant who has tooth sensitivity (self-reported symptoms).~Exclusion Criteria:~* A participant whose sensitivity could be caused by other factors or clinical pathology as established by the screening questionnaire, which also includes:~  * A participant who has been/is on multiple prescription medications to treat severe acid reflux on regular basis or considered surgery for acid reflux~ * A participant with full or partial denture~ * A participant who has undergone treatment within 6 months of screening or is currently under treatment for periodontal or gum disease~ * A participant with active periodontitis~ * A participant with active caries~ * A participant with any chronic and/or severe painful health conditions which lead to regular use pain medications (more than 3 days a week)~* A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients: potassium nitrate (5 percent \[%\]), sodium fluoride (0.15% weight/volume \[w/v\] fluoride ion), water, sorbitol, hydrated silica, glycerin, cocamidopropyl betaine, flavor, xanthan gum, titanium dioxide, sodium saccharin, sodium hydroxide, sucralose, yellow 10, blue 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sensodyne Fresh Mint Toothpaste (Type: OTHER): Participants will be asked to follow commercial tube instructions as recommended for sensitivity relief: Apply at least a 1-inch strip of the product onto a soft bristle toothbrush. Brush teeth thoroughly for at least 1 minute twice a day (morning and evening), and not more than 3 times a day, or as recommended by a dentist or doctor. Make sure to brush all sensitive areas of the teeth. Minimize swallowing, Spit out after brushing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males, or females of nonchildbearing potential~* 18 to 70 years of age~* Type 2 Diabetes Mellitus~* Liver fat \>/=8% by MRI-PDFF~* On stable dose of metformin monotherapy for at least 2 months (at a dose of at least 500 mg daily)~Exclusion Criteria:~* History of other liver disease~* Unable to have an MRI performed~* Significant weight loss in the previous month and/or participant in current weight loss program~* History of diabetic complications with end-organ damage

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Palacebo
- Low Dose (Type: EXPERIMENTAL): 150 mg
- High Dose (Type: EXPERIMENTAL): 300 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Parents of an adolescent between the ages of 9-17; OR a young adult patient between the ages of 18-26;~2. Adolescent/young adult has not yet received all three doses of the HPV vaccine.~3. Parent/young adult can read and converse in either English or Spanish~Exclusion Criteria:~1. Age \<18,~2. Prisoners~3. Decisionally challenged subjects~4. Those who cannot read and converse in either English or Spanish~5. Those who have received all 3 doses of the HPV vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Tailored intervention (Type: EXPERIMENTAL): Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
- Untailored Intervention (Type: OTHER): Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
- Usual Care (Type: OTHER): Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven stage IIIC or IV ovarian epithelial carcinoma, peritoneal carcinoma, or fallopian tube carcinoma~  * If biopsy is not available, evidence of adenocarcinoma by fine needle aspiration allowed if all of the following are true:~    * Presence of pelvic ovarian mass~   * Omental cake or other metastasis larger than 2 cm in the upper abdomen and/or regional lymph node metastasis~   * CA 125/carcinoembryonic antigen ratio greater than 25 (if ratio less than 25, barium enema or colonoscopy AND gastroscopy or radiological examination of the stomach must be negative for primary tumor)~   * Normal mammography (if CA 125/carcinoembryonic antigen ratio less than 25)~* Tumor greater than 2 cm, excluding ovaries, on laparoscopy or CT scan~* No brain or leptomeningeal metastases~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* WHO 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC greater than 3,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.25 times upper limit of normal (ULN)~Renal:~* Creatinine less than 1.25 times ULN~Other:~* No other serious disabling diseases contraindicating primary cytoreductive surgery or primary platin-based chemotherapy~* No other prior primary malignancies except carcinoma in situ of the cervix or basal cell carcinoma of the skin~* No psychological, familial, sociological, or geographical condition potentially preventing protocol compliance or follow-up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* No other prior procedures except diagnostic biopsy by laparotomy or laparoscopy

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is 7 to 80 years of age.~2. Has asthma~3. Has been identified as a candidate for inhaled corticosteroid (ICS) treatment~4. Is willing and able to perform Vivatmo pro™ testing~Exclusion Criteria:~1. Subject has used corticosteroids prior to enrollment.~2. Subject has other current serious medical conditions~3. Subject has not been clinically stable for at least 2 weeks prior to the study~4. Subject is unwilling or unable to perform Vivatmo pro testing

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Test Cohort (Type: EXPERIMENTAL): Subjects age 7 to 80 with asthma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV+~* Age 12 to \< 25 years~* History of no or one hepatitis B vaccination~* Not pregnant.~* Females engaging in sexual intercourse must be willing to practice an approved method of birth control throughout the completion of the vaccine phase of the study.~Exclusion Criteria:~* History of \> 1 hepatitis B vaccination~* Serologic evidence of past or present hepatitis B infection: anti-hepatitis B surface antigen (HBsAg), HBs-Ag or anti- hepatitis B core antigen (HBcAg)~* Previous allergic reaction to hepatitis A or B vaccinations or to yeast, thimerosal or aluminum.~* Active opportunistic infection or current treatment for known or suspected active serious bacterial infection at the pre-entry exam.~Presence of any known grade \>= 3 clinical or laboratory toxicity at the time of pre-entry per toxicity tables.~* Anticipation of long-term corticosteroid therapy or within 3 months preceding study randomization. Use of non-steroidal, anti-inflammatory agents and inhaled or topical corticosteroids are allowed.~* Receipt of any restricted medicine listed in the protocol section 8.1.3 within 3 months preceding randomization.~* Receipt of immune globulin product or plasma product within 6 months preceding randomization~* Receipt of licensed blood product or transfusion or any licensed vaccine within 4 weeks preceding randomization.~* Known or suspected diseases of the immune system, other than HIV, or treatment for a malignancy within 3 months of randomization.~* Other serious, acute or chronic medical or surgical conditions must be approved by the protocol chair.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Standard dose (20 mcg) of Hepatitis B vaccine.
- 2 (Type: ACTIVE_COMPARATOR): 40 mcg of Hepatitis B vaccine
- 3 (Type: ACTIVE_COMPARATOR): 20 mgc of Twinrix

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Efficacy of Lidocaine Plus Bupivacaine Versus Bupivacaine Alone Caudally

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) class 1.~* Patient underwent elective circumcision operation under general anesthesia and caudal analgesia.~Exclusion Criteria:~* Procedures simultaneously underwent another operation unrelated to circumcision.~* Patients who had unsuccessful caudal block.

- Gender: MALE
- Minimum Age: 2 Years
- Maximum Age: 11 Years
- Healthy Volunteers: None

Study Arms:
- Group B; (Type: None): Patients had 0.5 ml.kg-1 bupivacaine 0.25% caudally, the maximum given volume was 20 ml. N=42
- Group L; (Type: None): Patients had 0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1% caudally, the maximum given volume was 20 ml. N=44

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Regional Anesthesia Military Battlefield Pain Outcomes Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Major injury in one or more extremities requiring hospitalization and inpatient rehabilitation.~Exclusion Criteria:~* Major head trauma~* Cognitive deficits~* Inability to concentrate~* Poor judgment and impulse control~* Substantial hearing loss~* Bilateral upper extremity amputation with no alternate means to complete the survey forms

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
- Group 2 (Type: None): Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete